COX-2 Gene Promoter Haplotypes and Prostate Cancer Risk

Carcinogenesis - United Kingdom
doi 10.1093/carcin/bgh100
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Oxford University Press (OUP)

Related search

Association Between COX-2 Rs2745557 Polymorphism and Prostate Cancer Risk: A Systematic Review and Meta-Analysis

BMC Immunology
Immunology
2012English

Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors

Journal of Experimental Pharmacology
Molecular MedicinePharmacology
2012English

Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

2007English

Insulin Resistance-Related Gene Polymorphisms and Risk of Prostate Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

Protein Phosphatase 2A Subunit Gene Haplotypes and Proliferative Breast Disease Modify Breast Cancer Risk

Cancer
Cancer ResearchOncology
2009English

Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer

Frontiers in Pharmacology
Pharmacology
2012English

Fine-Mapping of IL16 Gene and Prostate Cancer Risk in African Americans

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2012English

Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter–Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth

PLoS ONE
Multidisciplinary
2016English

Inducible COX-2 Dominates Over COX-1 in Prostacyclin Biosynthesis: Mechanisms of COX-2 Inhibitor Risk to Heart Disease

Life Sciences
GeneticsMolecular BiologyPharmacologyBiochemistryMedicineToxicologyPharmaceutics
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy